In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.  

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.

In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.

In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma.  Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis. 

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC).  Through the lens of two NSCLC patients who received contrasting testing and treatment, listeners learn about the actionable oncogenic biomarker ROS1, which personalized testing methods are most effective for diagnosing ROS1 variants, and the latest advancements in ROS1-targeted therapy. These cases underscore the importance of aligning therapeutic approaches with evidence-based strategies and clinical guidelines by illustrating their direct impact on patient outcomes.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical presentation. The conversation highlights evolving treatment strategies – from first-generation TKIs to next-generation options – plus safety profiles, resistance mechanisms, and NCCN guideline recommendations. Tune in for practical insights on optimizing therapy and improving outcomes for patients with ROS1+ NSCLC.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, the role of DNA and RNA-based NGS, and why patient characteristics matter. Dr. Johnson also highlights breakthroughs in targeted therapies, emerging immunotherapies, and the critical role of clinical trials in improving outcomes.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy for extensive-stage small-cell lung cancer (ES-SCLC). They unpack the trial’s design and results, highlighting key safety and efficacy data that led to the FDA’s approval of this combination regimen on October 2, 2025. Tune in to hear expert perspectives on how this new indication will influence clinical practice and improve outcomes for ES-SCLC patients.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In this episode, Dr. Paul Conkling and Dr. David Spetzler explore the advantages of broad molecular profiling over smaller panels, emphasizing its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies. They discuss how AI is transforming treatment sequencing and improving patient outcomes, while also highlighting key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies. Dr. Spetzler further addresses the importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights, along with the challenges of clinical validation and regulatory approval.

Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.